-
Press Release
AveXis Community Statement on the Global Managed Access Program for AVXS-101
-
Press Release
AveXis Community Statement on the Coronavirus Disease (COVID-19)
-
Press Release
AveXis Community Statement on Global Managed Access Program for AVXS-101
-
Press Release
AveXis Statement on Changes to Senior Leadership Team
-
Press Release
AveXis Statement on Access to Zolgensma® (onasemnogene abeparvovec-xioi)
-
Press Release
AveXis Reports First Quarter 2018 Financial and Operating Results
-
Press Release
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
-
Press Release
AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
-
Press Release
AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology
-
Press Release
AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
-
Press Release
AveXis Enters into Licensing Agreement with Genethon
-
Press Release
AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results